Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?

被引：18
|
作者：
Kaul, Sanjay [1 ]
机构：
[1] Cedars Sinai Med Ctr, Div Cardiol, 8635 W Third St,Ste 790W, Los Angeles, CA 90048 USA
来源：
CIRCULATION | 2016年 / 134卷 / 02期
关键词：
clinical trial; diabetes mellitus; mortality; TRIAL;
D O I：
10.1161/CIRCULATIONAHA.116.022537
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：94 / +
页数：11
相关论文
共 50 条
  • [11] SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
    Riddle, Matthew C.
    Cefalu, William T.
    DIABETES CARE, 2018, 41 (12) : 2444 - 2447
  • [12] Options for empagliflozin in combination therapy in type 2 diabetes mellitus
    Hershon, Kenneth S.
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2016, 9 : 155 - 172
  • [13] Empagliflozin and cardiovascular endpoints in patients with type 2 diabetes mellitus
    Guthoff M.
    Der Nephrologe, 2016, 11 (3): : 217 - 218
  • [14] Usefulness of Empagliflozin Versus Oral Semaglutide for Prevention of Cardiovascular Mortality in Patients With Type 2 Diabetes Mellitus
    Hammerman, Ariel
    Moore, Candace Makeda
    Aboalhasan, Enis
    Azuri, Joseph
    Arbel, Ronen
    AMERICAN JOURNAL OF CARDIOLOGY, 2022, 170 : 128 - 131
  • [15] Mortality in type 2 diabetes mellitus
    Hollenberg, Norman K.
    JOURNAL OF HYPERTENSION, 2007, 25 (12) : 2381 - 2382
  • [16] Empagliflozin reduces cardiovascular events and mortality in type 2 diabetes
    Guthrie, Robert
    POSTGRADUATE MEDICINE, 2016, 128 (04) : 335 - 337
  • [17] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes REPLY
    Zinman, Bernard
    Lachin, John M.
    Inzucchi, Silvio E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (11): : 1094 - 1094
  • [18] Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
    Lai, Lee-Lee
    Vethakkan, Shireene Ratna
    Nik Mustapha, Nik Raihan
    Mahadeva, Sanjiv
    Chan, Wah-Kheong
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (02) : 623 - 631
  • [19] Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
    Anderson, John E.
    Wright, Eugene E., Jr.
    Shaefer, Charles F., Jr.
    DIABETES THERAPY, 2017, 8 (01) : 33 - 53
  • [20] Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
    John E. Anderson
    Eugene E. Wright
    Charles F. Shaefer
    Diabetes Therapy, 2017, 8 : 33 - 53
12345